Top

Osteoporosis International

Published in:

01-11-2013 | Original Article

Increased active PTH(1–84) fraction as a predictor of poor mortality in male hemodialysis patients

Authors: M. Inaba, S. Okuno, Y. Imanishi, E. Ishimura, T. Yamakawa, S. Shoji

Published in: Osteoporosis International | Issue 11/2013

Abstract

Summary

We reported previously that serum parathyroid hormone [PTH(1–84)]/intact PTH[PTH(1–84) + PTH(7–84)] ratio provides the better marker for parathyroid function and bone turnover state than serum PTH level itself. The present study demonstrated that higher PTH(1–84)/intact PTH ratio, but not serum PTH(1–84) and intact PTH, predicted higher all-cause mortality in 177 male hemodialysis patients.

Introduction

We reported that PTH(1–84)/intact PTH ratio provides a clinically relevant marker for parathyroid function and the resultant bone turnover state. The purpose of our study was to investigate the association of PTH(1–84)/intact PTH ratio with all-cause mortality (ACM) in male hemodialysis patients.

Methods

The study was performed for 70 months. Serum PTH in 177 male hemodialysis patients was measured with PTH(1–84)-specific whole PTH assay and intact PTH assay which cross-reacts with N-truncated PTH including PTH(7–84).

Results

The patients (n = 177) were divided into higher and lower halves based on serum levels of PTH(1–84)/intact PTH ratio (cutoff value, 0.484), intact PTH (143.8 pg/mL), and PTH(1–84) (64.1 pg/mL). In Kaplan–Meier analysis, the higher group in whole PTH/intact PTH ratio had significantly higher ACM than the lower group (P = 0.020 by log-rank test), in contrast with the insignificant difference between the higher and lower groups in intact PTH and PTH(1–84). Multivariate Cox regression hazard analysis identified higher log [PTH(1–84)/intact PTH ratio], but not log intact PTH or log PTH(1–84) as a significant independent predictor [hazard ratio 14.428 (95 % CI 2.486–83.728)] for ACM after adjustment for various factors including age, hemodialysis duration, presence/absence of diabetes mellitus, BMI, log C-reactive protein, serum albumin, calcium, and phosphate. The association existed between log [PTH(1–84)/intact PTH ratio] and ACM in those without vitamin D administration (n = 95).

Conclusion

Higher PTH(1–84)/intact PTH ratio, which provides a relevant marker for parathyroid function, may be a significant predictor of ACM in male hemodialysis patients.

Drechsler C, Krane V, Grootendorst DC, Ritz E, Winkler K, März W, Dekker F, Wanner C (2009) German diabetes and dialysis study investigators. Nephrol Dial Transplant 24(10):3151–3157PubMedCrossRef

Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15:2208–2218PubMedCrossRef

Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalanter-Zadeh K (2008) Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney Int 73:1296–1302PubMedCrossRef

Melamed ML, Eustace JA, Plantinga L, Jaar BG, Fink NE, Coresh J, Klag MJ, Powe NR (2006) Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int 70:351–357PubMedCrossRef

Yajima A, Inaba M, Tominaga Y, Ito A (2007) Minimodeling reduces the rate of cortical bone loss in patients with secondary hyperparathyroidism. Am J Kidney Dis 49:440–451PubMedCrossRef

Yajima A, Inaba M, Ogawa Y, Tominaga Y, Tanizawa T, Inou T, Otsubo O (2007) Significance of time-course changes of serum bone markers after parathyroidectomy in patients with uraemic hyperparathyroidism. Nephrol Dial Transplant 22:1645–1657PubMedCrossRef

Kurajoh M, Inaba M, Okuno S, Nagayama H, Yamada S, Imanishi Y, Ishimura E, Shoji S, Yamakawa T, Nishizawa Y (2011) Reduction of whole PTH/intact PTH ratio as a predictor of bone metabolism in cinacalcet treatment of hemodialysis patients with secondary hyperparathyroidism. 22(3):923–30

Shioi A, Taniwaki H, Jono S, Okuno Y, Koyama H, Mori K, Nishizawa Y (2001) Mönckeberg’s medial sclerosis and inorganic phosphate in uremia. Am J Kidney Dis 38:S47–S49PubMedCrossRef

Jono S, Shioi A, Ikari Y, Nishizawa Y (2006) Vascular calcification in chronic kidney disease. J Bone Miner Metab 24(2):176–181PubMedCrossRef

10.

Taniwaki H, Ishimura E, Tabata T, Tsujimoto Y, Shioi A, Shoji T, Inaba M, Inoue T, Nishizawa Y (2005) Aortic calcification in haemodialysis patients with diabetes mellitus. Nephrol Dial Transplant 20(11):2472–2478PubMedCrossRef

11.

Okuno S, Ishimura E, Kitatani K, Fujino Y, Kohno K, Maeno Y, Maekawa K (2007) Presence of abdominal aortic calcification is significantly associated with all-cause and cardiovascular mortality in maintenance hemodialysis patients. Am J Kidney Dis 49:417–425PubMedCrossRef

12.

Kobayashi I, Shidara K, Okuno S, Yamada S, Imanishi Y, Mori K, Ishimura E, Shoji S, Yamakawa T, Inaba M (2012) Higher serum bone alkaline phosphatase as a predictor of mortality in male hemodialysis patients. Life Sci 90(5–6):212–218PubMedCrossRef

13.

Kohno K, Inaba M, Okuno S, Maeno Y, Maekawa K, Yamakawa T, Ishimura E, Nishizawa Y (2009) Association of reduction in bone mineral density with mortality in male hemodialysis patients. Calcif Tissue Int 84:180–185PubMedCrossRef

14.

Maeno Y, Inaba M, Okuno S, Kohno K, Maekawa K, Yamakawa T, Ishimura E, Nishizawa Y (2009) Significant association of fracture of the lumbar spine with mortality in female hemodialysis patients: a prospective observational study. Calcif Tissue Int 85:310–316PubMedCrossRef

15.

Inaba M, Nakatsuka K, Imanishi Y, Watanabe M, Mamiya Y, Ishimura E, Nishizawa Y (2004) Technical and clinical characterization of the Bio-PTH (1–84) immunochemiluminometric assay and comparison with a second-generation assay for parathyroid hormone. Clin Chem 50:385–390PubMedCrossRef

16.

Inaba M, Okuno S, Imanishi Y, Ueda M, Yamakawa T, Ishimura E, Nishizawa Y (2005) Significance of bio-intact PTH(1–84) assay in hemodialysis patients. Osteoporos Int 16:517–525PubMedCrossRef

17.

Kawata T, Imanishi Y, Kobayashi K, Onoda N, Takemoto Y, Tahara H, Okuno S, Ishimura E, Miki T, Ishikawa T, Inaba M, Nishizawa Y (2005) Direct in vitro evidence of extracellular Ca2+−induced amino-terminal truncation of human parathyroid hormone (1–84) by human parathyroid cells. J Clin Endocrinol Metab 90(10):5774–5778PubMedCrossRef

18.

Zitt E, Kirsch AH, Haueis M, Strasak A, Neyer U, Mayer G, Rosenkranz AR (2011) The PTH (1–84)/non-PTH (1–84) ratio is a risk factor for cardiovascular events in hemodialysis patients. Clin Nephrol 75(4):309–318PubMedCrossRef

19.

Inaba M, Okuno S, Imanishi Y, Yamada S, Shioi A, Yamakawa T, Ishimura E, Nishizawa Y (2006) Role of fibroblast growth factor-23 in peripheral vascular calcification in non-diabetic and diabetic hemodialysis patients. Osteoporos Int 17:1506–1513PubMedCrossRef

20.

Inaba M, Terada M, Nishizawa Y, Shioi A, Ishimura E, Otani S, Morii H (1999) Protective effect of an aldose reductase inhibitor against bone loss in galactose-fed rats: possible involvement of the polyol pathway in bone metabolism. Metabolism 48:904–909PubMedCrossRef

21.

Gao P, Scheibel S, D’Amour P, John MR, Rao SD, Schmidt-Gayk H, Cantor TL (2001) Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1–84: implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res 16:605–614PubMedCrossRef

22.

Souberbielle JC, Boutten A, Carlier MC, Chevenne D, Coumaros G, Lawson-Body E, Massart C, Monge M, Myara J, Parent X, Plouvier E, Houillier P (2006) Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int 70:345–350PubMedCrossRef

23.

Arnaud CD, Pun KK (1992) Metabolism and assay of parathyroid hormone. In: Coe FL, Favus MJ (eds) Disorders of bone and mineral metabolism. Raven Press, New York, pp 107–122

24.

Reichel H, Esser A, Roth HJ, Schmidt-Gayk H (2003) Influence of PTH assay methodology on differential diagnosis of renal bone disease. Nephrol Dial Transplant 18:759–768PubMedCrossRef

25.

Roth HJ (2000) Elecsys parathyroid hormone (PTH) not detecting the large PTH fragment hPTH (7–84)? Clin Lab 46:295–299PubMed

26.

Hiroyuki Y, Motomiya Y, Uchida K, Akizawa T (2002) Development and clinical application of Whole PTH (PTH1-84) kit. Jpn J Med Pharm Sci 48:243–247

27.

Inomata K, Yamashita H, Yamamoto A, Yukishita M, Adachi M (2004) Influence of 25-hydroxyvitamin D concentration on the reference range of intact PTH. Osteoporosis Japan 12:449–456

28.

Shoji T, Shinohara K, Kimoto E, Emoto M, Tahara H, Koyama H, Inaba M, Fukumoto S, Ishimura E, Miki T, Tabata T, Nishizawa Y (2004) Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D₃ users in a haemodialysis population. Nephrol Dial Transplant 19(1):179–184PubMedCrossRef

29.

Kurajoh M, Inaba M, Yamada S, Imanishi Y, Tsuchida T, Ishimura E, Nishizawa Y (2008) Association of increased active PTH(1–84) fraction with decreased GFR and serum Ca in predialysis CRF patients: modulation by serum 25-OH-D. Osteoporos Int 19(5):709–716PubMedCrossRef

30.

Ishimura E, Okuno S, Kitatani K, Kim M, Shoji T, Nakatani T, Inaba M, Nishizawa Y (2002) Different risk factors for peripheral vascular calcification between diabetic and non-diabetic haemodialysis patients—importance of glycaemic control. Diabetologia 45(10):1446–1448PubMedCrossRef

31.

Block GA, Zaun D, Smits G, Persky M, Brillhart S, Nieman K, Liu J, St Peter WL (2010) Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients. Kidney Int 78(6):578–589PubMedCrossRef

32.

Kawata T, Nagano N, Obi M, Miyata S, Koyama C, Kobayashi N, Wakita S, Wada M (2008) Cinacalcet suppresses calcification of the aorta and heart in uremic rats. Kidney Int 74(10):1270–1277PubMedCrossRef

33.

Jean G, Lataillade D, Genet L, Legrand E, Kuentz F, Moreau-Gaudry X, Fouque D (2011) ARNOS study investigators. Association between very low PTH levels and poor survival rates in haemodialysis patients: results from the French ARNOS cohort. Nephron Clin Pract 118(2):c211–c216PubMedCrossRef

34.

Shidara K, Inaba M, Okuno S, Imanishi Y, Yamakawa T, Ishimura E, Kumeda Y, Nishizawa Y (2007) Influence of nutritional status on serum large N-truncated PTH, but not PTH(1–84) in hemodialysis patients. Biomed Pharmacother 61(2–3):142–147PubMedCrossRef

35.

Mehrotra R, Duong U, Jiwakanon S, Kovesdy CP, Moran J, Kopple JD, Kalantar-Zadeh K (2011) Serum albumin as a predictor of mortality in peritoneal dialysis: comparisons with hemodialysis. Am J Kidney Dis 58(3):418–428PubMedCrossRef

Title: Increased active PTH(1–84) fraction as a predictor of poor mortality in male hemodialysis patients
Authors: M. Inaba
S. Okuno
Y. Imanishi
E. Ishimura
T. Yamakawa
S. Shoji
Publication date: 01-11-2013
Publisher: Springer London
Published in: Osteoporosis International / Issue 11/2013
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-012-2245-x

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Increased active PTH(1–84) fraction as a predictor of poor mortality in male hemodialysis patients

Abstract

Summary

Introduction

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 11/2013

Bone mass and density in preadolescent boys with and without Down syndrome

Pseudoarthrosis in atypical femoral fracture: case report

Secondary prevention of osteoporotic fractures—an “OPTIMAL” model of care from Singapore

Bisphosphonate use and subsequent hip fracture in South Korea

The role of the gastrointestinal tract in calcium homeostasis and bone remodeling

The efficacy of calcium supplementation alone in elderly Thai women over a 2-year period: a randomized controlled trial